Duyuru • Apr 23
Curexo Inc. announced that it expects to receive KRW 500 million in funding Curexo Inc. announced a private placement of Series 3 Unregistered Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 500,000,000 on April 22, 2026. The transaction involves participation from individual investor Ha Yong-chan for KRW 200,000,000, Yoon Seon-joong for KRW 200,000,000 and Yoo Jun-il for KRW 100,000,000. The Bonds are 100% convertible into 31,174 Common Shares of the company at a conversion price of KRW 16,039 and the conversion billing period will start from April 30, 2027 till March 31, 2029. The Bonds carry an interest rate of 3% and maturity interest of 4%. The Bonds have a maturity date of April 30, 2029. The transaction has been approved by Board of Directors of the company. The securities being issued in this transaction are on a hold period for 1 year. The transaction is expected to close on April 30, 2026. Duyuru • Feb 06
Curexo Inc., Annual General Meeting, Mar 26, 2026 Curexo Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea New Risk • Feb 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (74% accrual ratio). Duyuru • Feb 08
Curexo Inc., Annual General Meeting, Mar 26, 2025 Curexo Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea New Risk • Jan 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change). New Risk • Jan 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding). New Risk • Jul 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (74% accrual ratio). Minor Risk Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • May 22
CUREXO Corp. Spinal Surgery Robot, 'Cuvis-Spine' Acquires FDA (US) Licensing CUREXO Corp. announced their independently developed spinal surgery robot 'CUVIS-spine' has acquired FDA (US) licensing. This FDA (US) license, followed by Korea (2019) and Europe CE (2020) certificate is the 3rd license that they have acquired and now their product can be supplied to all countries. Currently, 2 'CUVIS-spine's are being used in Severance Hospital (Korea) and 1 has been exported to an Australian medical facility company. CUREXO also plans to expand their focus on global markets including the US and Europe. Spinal surgery robot 'CUVIS-spine' is a next-gen spinal surgery robot that guides the insertion of a pedicle screw according to the surgery plan. It uses a high precision robot arm, wireless one-step, navigation based on a real-time GPS sensor to provide precise, safe and faster surgery compared to traditional manual surgery. Also, it minimizes the filming and reduces the radiation exposure of both patients and medical staff. Both 2-dimensional filming (C-arm) and 3-dimensional filming (O-arm) are applicable with this solution which provides great expandability. With the Wireless One-step and the robot system, it allows multiple steps (Needle, K-wire, Dilation, Tapping) of traditional manual surgery to be performed with one surgery tool and it reduces surgery duration greatly. It allows Minimally Invasive Surgery (MIS) which means that the patient's recovery time will be quicker compared to manual surgery. Duyuru • May 21
Curexo Inc. announced that it has received KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm On May 20, 2021, Curexo Inc. (KOSDAQ:A060280) closed the transaction. Duyuru • May 14
Curexo Inc. announced that it expects to receive KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm and another investor Curexo Inc. (KOSDAQ:A060280) announced a private placement of round 2 non-guaranteed private equity convertible bonds for gross proceeds of KRW 15,000,000,000 on May 13, 2021. The bonds do not carry any coupon. The bonds will mature on May 20, 2026. The transaction will include participation from new investors Korea Investment & Securities Co., Ltd., Investment Arm and Global Robot Healthcare New Technology Business Fund. The bonds are 100% convertible into 1,434,165 common shares at a price of KRW 10,459 per share. The conversion period of the bonds is from May 20, 2022 to April 20, 2026. The transaction is expected to close on May 20, 2021. The transaction has been approved by the board of directors of the company. Duyuru • Feb 10
Curexo Inc., Annual General Meeting, Mar 24, 2021 Curexo Inc., Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Jan 05
New 90-day high: ₩7,170 The company is up 14% from its price of ₩6,310 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 9.0% over the same period.